Results 231 to 240 of about 1,549,234 (325)

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

Advanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang, Wing Yan Chung, Serena M. Pulente, Yubin Lei, Khang Nguyen, Eddie Tam, Nadya M. Morrow, Ilka Lorenzen‐Schmidt, Fengxia Xiao, Augusto Zani, Dylan Burger, Hye Kyoung Sung, Erin E. Mulvihill, Gary Sweeney   +13 more
wiley   +1 more source

Editorial: Novel therapeutics for urological cancers. [PDF]

Front Pharmacol
Tang S, Li B.
europepmc   +1 more source

CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads

Advanced Healthcare Materials, EarlyView.
In this paper researchers introduce CORE LNPs, a new class of lipid nanoparticles engineered to redirect mRNA expression away from the liver and into the spleen, a key immune organ. By combining chemical design with computational tools, they created cholesterol analogs that enable precise spleen‐targeted expression, providing greater applications for ...
Eshan A. Narasipura, Vincent Fung, Rachel VanKeulen‐Miller, Palas B. Tiwade, Owen S. Fenton   +4 more
wiley   +1 more source

An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics. [PDF]

Int J Toxicol
Sisler JD, Andersson P, Brown A, Harbison C, Irrechukwu O, Lightfoot H, Maes M, Mukherjee S, Parry JD, Schumacher J, Westlind Johnsson A, Yang Y, Harper TA.   +12 more
europepmc   +1 more source

Model‐Driven Optimization of Subcutaneous Polymer Prodrugs Achieves Cancer Remission in Mice

Advanced Healthcare Materials, EarlyView.
A pharmacokinetics/pharmacodynamics (PK/PD) model was developed to evaluate multiple dosing regimens for subcutaneously administered water‐soluble polymer prodrug for cancer therapy. The model enabled prediction of in vivo performance and contributed to the optimization of anticancer efficacy.
Anne Rodallec, Randy Lee, Jingming Cao, Sophie Marolleau, Julien Nicolas, Sébastien Benzekry   +5 more
wiley   +1 more source

Editorial: Next-generation PROTACs in oncology and beyond: exploring therapeutic targets and their degraders. [PDF]

Front Pharmacol
Liao D, Bandyopadhyay D.
europepmc   +1 more source

Respiratory Organ‐on‐a‐Chip for Disease Modeling: From Architecture to Functional Integration

Advanced Healthcare Materials, EarlyView.
Respiratory organ‐on‐a‐chip (ROC) models capture key mechanical and cellular cues of the human respiratory system, enabling quantitative dissection of disease mechanisms. This review links ROC architectures to disease modeling, functional integration, and commercialization, and proposes a decision framework that aligns model complexity with mechanistic
Jinzhuo Hu, Yongjie Tang, Sidi Liu, Tao Xu, Qian Liu   +4 more
wiley   +1 more source

DSM-5 Changes, COVID-19, and ADHD Diagnosis Rates in Individuals Younger Than 30 Years.

JAMA Netw Open
Cui Z, Ambasta A, Thompson W, Bassett K, Carney G, Dormuth C.   +5 more
europepmc   +1 more source